Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $19.1800 (14.92%) ($17.0500 - $19.7000) on Wed. May. 6, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.86% (three month average) | RSI | 78 | Latest Price | $19.1800(14.92%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 11.3% a day on average for past five trading days. | Weekly Trend | TGTX advances 9.9% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(62%) ARKG(56%) IBB(54%) ARKK(53%) IWO(52%) | Factors Impacting TGTX price | TGTX will decline at least -4.43% in a week (0% probabilities). VIXM(-33%) VXX(-31%) UUP(-14%) DRIV(-2%) TLT(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -4.43% (StdDev 8.86%) | Hourly BBV | 0 () | Intraday Trend | 9.2% | | | |
|
5 Day Moving Average | $14.27(34.41%) | 10 Day Moving Average | $13.5(42.07%) | 20 Day Moving Average | $12.36(55.18%) | To recent high | 0% | To recent low | 168.6% | Market Cap | $2.429b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |